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Purpose: Pediatric germ cell tumors are rare, representing about 3% of childhood malig-
nancies in children less than 15 years of age, presenting in neonates or adolescents with a
greater incidence noted in older adolescents. Aberrations in primordial germ cell prolifera-
tion/differentiation can lead to a variety of neoplasms, including teratomas, embryonal
carcinoma, choriocarcinoma, and yolk sac tumors.
Patients and Methods: Three Finnish families with varying familial germ cell tumors
were identified, and whole-genome sequencing was performed using an Illumina sequencing
platform. In total, 22 unique subjects across the three families were sequenced. Family 1
proband (female) was affected by malignant ovarian teratoma, Family 2 proband (female)
was affected by sacrococcygeal teratoma with yolk sac tumor in the setting of Cornelia de
Lange syndrome, and Family 3 proband (male) was affected by malignant testicular tera-
toma. Rare variants were identified using an autosomal recessive or de novo model of
inheritance.
Results: For family 1 proband (female), an autosomal recessive or de novo model of inheritance
identified variants of interest in the following genes: CD109, IKBKB, and CTNNA3, SUPT6H,
MUC5AC, and FRG1. Family 2 proband (female) analysis identified gene variants of interest in
the following genes: LONRF2, ANO7, HS6ST1, PRB2, and DNM2. Family 3 proband (male)
analysis identified the following potential genes: CRIPAK, KRTAP5-7, and CACNA1B.
Conclusion: Leveraging deep pedigrees and next-generation sequencing, rare germline
variants were identified that were enriched in three families from Finland with a history of
familial germ cell tumors. The data presented support the importance of germline mutations
when analyzing complex cancers with a low somatic mutation landscape.
Keywords: genomics, familial germ cell tumors, next generation sequencing, germline
analysis
Introduction
Pediatric germ cell tumors (GCT) represent about 3% of all childhood malignancies
for children less than 15 years of age; this incidence increases to about 15% in
adolescence and young adulthood.1 These tumors may arise from the gonads or
extra-gonadal tissue. There are five subtypes of pediatric GCT: teratoma, germi-
noma, yolk sac tumor (also known as endodermal sinus tumor), embryonal carci-
noma, and choriocarcinoma, as well as mixed malignant subtypes.1–3 Although
infantile and pediatric GCT are biologically distinct from GCT of older adolescents
and adults, treatment for all GCT is essentially the same and generally grounded in
large doses of platinum-based chemotherapy combined with surgery. Thus, younger
patients suffer more severe side effects from treatment.2,4
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Predisposition to developing ovarian and testicular ter-
atomas has been reported in families with multiple
affected members.3 While the exact mechanisms under-
lying GCT development remain unclear, abnormalities in
the KIT-ligand (KITLG) and KRAS pathway are thought to
play a role.5,6 Amplifications in chromosome 12p and X
chromosome have been implicated in nonseminomatous
GCT. Yolk sac tumors also show gains in chromosomes
1q, 11q, 20q, as well as gains in chromosome 22; losses in
chromosome 1p, 6q, and 16q have also been reported.7
There is evidence to support that methylation plays a
role in GCT biology, and that methylation patterns identi-
fied in GCT can distinguish the five sub-types.8 Based on
prevailing literature and our experience with families
enriched with germ cell malignancies, germline variant
that predisposes a progenitor germ cell to malignant trans-
formation or makes the microenvironment more permis-
sive to tumor growth is likely to be a strong candidate for
unraveling the complex biology of these cancers.
Next-generation sequencing (NGS) has significantly
advanced our understanding of the genomic landscape of
familial cancers.2 Combining deep phenotyping with deep
sequencing has the potential to identify key oncogenes
involved with rare and aggressive cancers. The goal of
this study was to apply these techniques to 3 independent
families from Finland with an extensive history of neopla-
sia, but no known genomic lesions. Of interest, the people
of Finland have a unique ancestry marked by a population
bottleneck followed by geographic isolation on a
peninsula.9 Consequently, the Finnish population has an
enrichment in rare genetic variants. Our study leverages
the distinctive genetics of this population.
Patients and Methods
Subject Enrollment
Three families from Finland were enrolled for this study.
The study was approved by the ethical committee of
Helsinki University Hospital, Helsinki, Finland. Written
informed consent was obtained from all subjects and/or
their parents, as well as the relatives from whom the
samples were obtained for this study. A total of 22 unique
subjects were sequenced across the 3 families, n=4, n=11,
and n=7, respectively (Supplemental Table 1). Family 1
proband had a malignant ovarian teratoma, diagnosed at 8
years of age, with a family history of ovarian teratoma
(Supplemental Table 1). Family 2 proband was diagnosed
with a neonatal sacrococcygeal teratoma and a subsequent
yolk sac tumor at 1.5 years of age, with a family history of
malignancies (NOS) (Supplemental Table 1). Family 3 had
a proband with a malignant testicular teratoma, diagnosed
at 1 year of age, with a family history of malignancies
(NOS) (Supplemental Table 1). Peripheral blood was col-
lected from each proband and family members.
De-identified analysis of genomic data from the con-
sented patients was conducted at Nemours (Dr. Crowgey)
with IRB research determination (IRB# 1327922–1).
Whole-Genome Sequencing (WGS) and
Genome Alignment
Whole-genome sequencing was conducted at Washington
University School of Medicine by the McDonnell Genome
Institute. Whole-genome sequencing was conducted using
the NovaSeq 6000 high-throughput sequencing platform
(Illumina, San Francisco, CA) at a depth of coverage of
30X. Samples were prepared using the TruSeq whole
genome library preparation (Illumina). Fastq files were
processed via fastqc for data quality (Babraham Institute)
and trimmed based on adaptor sequences and quality
(cutadapt). Trimmed reads were mapped to the human
genome hg19 via bwa mem.10 Genome analysis toolkit
(GATK) best practices, base quality score recalibration,
indel realignment, and duplicate read removal were fol-
lowed to generate a combined variant call file (VCF) using
Haplotyper for all samples analyzed.11–13
Variant Annotation and Data Analysis
VCFs were annotated using VarSeq version 2.2.0 (Golden
Helix®). Specifically, variants were annotated using: ExAC
Variant Frequencies 0.3, gnomAD exomes and genome var-
iant frequencies 2.1.1,14 dbSNP 151 (http://www.ncbi.nlm.
nih.gov/SNP/), Ensemble Genes 87, and functional predic-
tions were determined via sift,15 polyphen2 HVAR,16 muta-
tion taster,17 mutationAssessor,18 FATHMM,19 and
FATHMM MKL coding. At least three of the functional
predictions needed to predict the variant as damaging.
Variants were filtered based on the following inheritance
patterns when appropriate autosomal recessive, and de
novo, using the following criteria: read depth >10, genotype
qualities >20, MAF ExAC <0.01, MAF gnomAD <0.01, and
effect of mutation (loss of function or missense for coding
variants). The same logic was applied for non-coding var-
iants located in introns and non-exonic (intergenic) locations.
A variant was considered as autosomal recessive for
proband 1 and 2 if both the mother and father were carriers
Crowgey et al Dovepress
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(0/1), unaffected siblings were either carriers or wildtype
(0/1 or 0/0), and the proband was homozygous alternative
(1/1). Additionally, for family 2 proband, the unaffected
extended family members in the pedigree were used to
further filter out variants if they were a homozygous alter-
native (1/1) genotype. Variants were considered as de novo
for proband 1 and 2 if both the mother and father were
homozygous wildtype (0/0), and the unaffected siblings
were also homozygous wildtype (0/0). Additionally, for
family 2 proband, the unaffected extended family mem-
bers in the pedigree were used to further filter out variants
if they were a carrier (0/1). For proband 3, unfortunately
the mother’s sample was not available for sequencing. The
same logic as above for probands 1 and 2 was applied,
except that the mother’s parents’ genotypes were used in
replacement.
Results
Family 1
Four subjects were sequenced in Family 1 pedigree:
mother, father, proband (ovarian teratoma), and unaffected
sibling (Figure 1). A history of ovarian teratoma was noted
by the primary care physician (Supplemental Table 1);
however, germline samples from these extended family
members were not available for sequencing. Using an
autosomal recessive analysis, three variants of interest
were identified in the following genes: CD109
(rs7741152), IKBKB (rs140485496), and CTNNA3
(rs192093851) (Table 1). All of the variants identified
were rare within the other Finnish families analyzed with
CD109 and IKBKB alleles only identified in Family 1, and
1 allele count outside of Family 1 for rs192093851
(CTNNA3). It was noted that all three variants had a
<0.01 minor allele frequency (MAF) within the gnomAD
database; however, they were >0.01 within the Finnish-
specific genomes within gnomAD (Table 1). Inhibitor of
NF-κB kinase subunit beta (IKBKB) is associated with
immunodeficiency disorders (IMD15B and 15A) and is a
Figure 1 Family 1 pedigree. Four family members were sequenced via whole-
genome sequencing: proband, mom, dada, and unaffected sister. The proband,
black circle, was a malignant ovarian teratoma. Females are represented as circles;
males are represented as squares. The number next to the pedigree represents the
de-identified subject ID.
Figure 2 Family 2 pedigree. Eleven subjects were sequenced via whole-genome sequencing: proband, unaffected brother, unaffected sister, mother, father, two paternal
aunts, paternal grandmother, 2 paternal great aunts, and a paternal cousin. The proband, black circle, was a sacrococcygeal teratoma – yolk sac tumor. Females are
represented as circles; males are represented as squares. The number next to the pedigree represents the de-identified subject ID.
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serine kinase that plays a key role in the NF-κB signaling
pathway. Gene variants and expression data have linked
IKBKB with prostate and ovarian cancers.20 Of interest,
IKBKB has been associated with KRAS, which is a known
oncogene linked to GCTs.21
The de novo analysis identified 14 rare variants
within proband one across 10 unique genes (Table 1).
Nine of the variants had known RefSeq (rs#) identifica-
tion numbers in the dbSNP database and MAF of >0.01
in the gnomAD genome database as well as within the
Figure 3 Family 3 pedigree. Seven subjects were sequenced via whole-genome sequencing: proband, unaffected siblings, data, maternal uncle, and maternal grandparents.
Females are represented as circles; males are represented as squares. The number next to the pedigree represents the de-identified subject ID.
Figure 4 Non-coding variants identified in the probands. Rare non-coding variants were identified in introns (left bars) and non-exonic regions (intergenic, right bars) per
each proband. A variant was considered to be known if it was listed in dbSNP 151. Known homozygous variants are in blue, novel homozygous variants are in orange, known
heterozygous variants are in grey, and novel heterozygous variants are in yellow.
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Finnish-specific genomes within gnomAD (Table 1). Of
interest, SUPT6H, a histone chaperone, has previously
been shown to control estrogen-related transcription and
linked to cancer.22 Additionally, MUC5AC has been
associated with ovarian tumors23 and FRG1 expression
levels have been shown to be aberrant in several
cancers.
Family 2
Eleven subjects were sequenced in Family 2 pedigree:
proband (sacrococcygeal teratoma – yolk sac tumor),
unaffected brother with a benign sacrococcygeal cyst,
unaffected sister, mother, father, two paternal aunts,
paternal grandmother, 2 paternal great aunts, and a
paternal cousin (Supplemental Table 1; Figure 2). Of
interest, the unaffected brother and nephew (unaffected
sister) have a history of benign dermoid cysts (sacro-
coccygeal and ophthalmic area). Furthermore, the pro-
band’s great grandfather (maternal side) had prostate
cancer, and a great grandmother with stomach cancer,
who has a daughter with leukemia and a granddaughter
with cancer. An autosomal recessive analysis identified
two rare variants in the following genes LONRF2
(rs116702638) and ANO7 (rs148609049) (Table 2). It
was noted that all three variants had a <0.01 MAF
within the gnomAD database; however, they were
Crowgey et al Dovepress
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Table 2 Rare Autosomal Recessive and De Novo Variants Identified in Family 2 Proband
Inhertiance
Pattern
Chr:
Position
Ref/Alt ID Father Mother Proband Sister Brother Aunt Aunt Grandma Great
aunt
95/98 96/98 97/98 105/
98
106/98 108/
98
112/
98
107/98 111/98
Autosomal
recessive
2:100915330 G/T rs116702638 0/1 0/1 1/1ʹ 0/1 0/1 0/1 0/1 0/1 0/1
2:242128114 C/T rs148609049 0/1 0/1 1/1ʹ 0/0 0/1 0/0 0/1 0/1 0/0
De novo 1:152278769 -/CC rs1205280854 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
6:43155555 CC/- rs1235342930 0/0 0/0 0/1 0/0 0/0 0/0 0/1 0/0 0/0
6:43155558 -/ACG rs1217118305 0/0 0/0 0/1 0/0 0/0 0/0 0/1 0/0 0/0
1:152278771 TG/- rs1407703398 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
1:152278831 -/TTG rs1448728360 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
2:129025758 C/A rs142919429 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
3:195506483 TGTCGGTGAC
AGGAAGGGGG
GTGGCGTGAC
CTGTGGATGC
TGAGGAAC/-
rs1560301180 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
3:195512233 -/GCCGAGGAA
ACGTTGGTGA
CAGGAAGAC
GGGTGGTGT
CACCTGTGGAA
rs529636680 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
6:43155547 C/T rs1300018649 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
6:43155560 -/GA rs1264139231 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
6:43155560 T/C rs1489405189 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
6:43155563 ACT/- rs1189505569 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
11:1093483 GT/- rs747244421 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
12:11546859 -/CCTTGAGG
CTGGTTGCC
TCCTTGTGG
GGGTGCTCC
TTGTGGCTT
TCCTGGAGG
AGG
0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
12:40876971 C/A rs769109166 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
12:40876979 A/C rs1273078187 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
19:10908156 TCAGAGCTG/- rs1295151630 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
19:41811728 -/CCCCCCCA 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
19:52888076 -/ATGAGGTC
AGGAGATCG
AGACCATCC
TGGCTAACAA
GGTG
0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0
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>0.01 within the Finnish-specific genomes within
gnomAD (Table 1). Variant rs148609049 has previously
been published as a germline variant that associates with
significantly shorter survival rates in prostate cancer
subjects.24 Aberrant methylation patterns for LON pep-
tidase N-terminal domain and RING finger protein 2
(LONRF2) have been noted in rectal adenocarcinoma.
Of interest, ANO7 is associated with aggressive prostate
cancer.24
The de novo analysis identified 19 rare variants within
proband two across 10 unique genes (Table 2). Sixteen of
the variants were found in dbSNP with MAF of >0.01 in the
gnomAD genome database and within the Finnish-specific
genomes within gnomAD (Table 2). Of interest HS6ST1,
PRB2, and DNM2 have been previously linked to
cancers.25,26
Family 3
Seven subjects were sequenced in Family 3 pedigree:
proband (malignant testicular teratoma), un-affected sib-
lings, dad, uncle (maternal), grandparents (maternal)
(Supplemental Table 1; Figure 3). Two InDels were iden-
tified in this family using an autosomal recessive pattern in
the following genes (Table 3): CRIPAK and KRTAP5-7.
CRIPAK encodes for a cysteine-rich PAK1 inhibitor pro-
tein that negatively regulates PAK1 expression. PAKs are a
Great
aunt
Cousin Gene
Names
HGVS c. (Clinically Relevant) HGVS p. (Clinically Relevant) Effect GnomAD GnomAD
European
(Finnish)110/98 109/98
0/1 0/0 LONRF2 NM_198461.3:c.1444C>A NP_940863.3:p.His482Asn 0.008377 0.0201
0/1 0/0 ANO7 NM_001001891.3:c.88C>T NP_001001891.2:p.Arg30Ter 0.007657 0.03571
0/0 0/0 FLG NM_002016.1:c.8593_8594insGG NP_002007.1:p.Ala2865Glyfs frameshift_variant 0.003439 0.02396
0/0 0/0 CUL9 NM_015089.3:c.1686_1687delCC NP_055904.1:p.Leu563Alafs frameshift_variant 0.003898 0
0/0 0/0 CUL9 NM_015089.3:c.1688_1689ins
ACG
NP_055904.1:p.Leu563_Leu5
64insArg
disruptive_inframe_insertion 0.006126 0
0/0 0/0 FLG NM_002016.1:c.8590_8591delCA NP_002007.1:p.His2864Cysfs frameshift_variant
0/0 0/0 FLG NM_002016.1:c.8531_8532ins
CAA
NP_002007.1:p.Glu2844delins
AspLys
disruptive_inframe_insertion
0/0 0/0 HS6ST1 NM_004807.2:c.1214G>T NP_004798.3:p.Ser405Ile missense_variant 0.001622 0.0008978
0/0 0/0 MUC4 NM_018406.6:c.11921_11968del
GTTCCTCAGCATCCACAG
GTCACGCCACCCCCC
TTCCTGTCACCGACA
NP_060876.5:p.Arg3974_Thr
3990delinsPro
disruptive_inframe_deletion
0/0 0/0 MUC4 NM_018406.6:c.6218_6219insTT
CCACAGGTGACACCACCCG
TCTTCCTGTCACCAACGTTT
CCTCGGC
NP_060876.5:p.
Gly2076_His2077insAspThrThr
ArgLeuPro
ValThrAsnValSerSerAlaSerThrGly
disruptive_inframe_insertion 0.00004043 0
0/0 0/0 CUL9 NM_015089.3:c.1678C>T NP_055904.1:p.Leu560Phe missense_variant 0.004704 0
0/0 0/0 CUL9 NM_015089.3:c.1690_1691insGA NP_055904.1:p.Leu564Argfs frameshift_variant
0/0 0/0 CUL9 NM_015089.3:c.1691T>C NP_055904.1:p.Leu564Pro missense_variant 0 0
0/0 0/0 CUL9 NM_015089.3:c.1694_1696del
ACT
NP_055904.1:p.Asn565_Ser
566delinsThr
disruptive_inframe_deletion 0.004741 0.00003985
0/0 0/0 MUC2 NM_002457.4:c.5296_5297delGT NP_002448.4:p.Val1766Thrfs frameshift_variant
0/0 0/0 PRB2 NM_006248.3:c.153_154insCCTC
CTCCAGGAAAGCCACAAG
GAGCACCCCCACAAGGA
GGCAACCAGCCTCAAGG
NP_006239.3:p.Ser52Profs frameshift_variant
0/0 0/0 MUC19 NM_173600.2:c.10217C>A NP_775871.2:p.? missense_variant 0.002807 0.0003193
0/0 0/0 MUC19 NM_173600.2:c.10225A>C NP_775871.2:p.? missense_variant 0.001104 0
0/0 0/0 DNM2 NM_001005360.2:c.1336-1006_13
36-998delTCAGAGCTG
inframe_deletion 0.009196 0.000204
0/0 0/0 HNRNPUL1 NM_007040.5:c.2409_2410insCC
CCCCCA
NP_008971.2:p.Thr804Profs frameshift_variant
0/0 0/0 ZNF880 NM_001145434.1:c.1242_1243ins
ATGAGGTCAGGAGATCGAG
ACCATCCTGGCTAACAAGGTG
NP_001138906.1:p.Lys415Metfs frameshift_variant
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family of proteins that are involved in cytoskeletal
dynamics, cell survival and proliferation and have been
well associated with cancers.27 The de novo analysis iden-
tified 22 rare variants in 17 unique genes. Aberrant expres-
sion levels of CACNA1B have previously been associated
with cancers.28 Of interest, TXNDC2 is solely expressed in
testis and is predicted to regulate disulfide bonds, and
TFE3 is a transcription factor linked to cancers and is
ubiquitous in fetal and adult tissues.
Non-Coding Variant Analysis
Rare variants (gnomAD MAF <0.01) in non-coding
regions of the genome were analyzed, introns or intergenic
regions. Heterozygous variants were only considered for a
proband if the parents and unaffected siblings were homo-
zygous wildtype (0/0), and homozygous variants were
only considered for a proband if the parents and unaffected
siblings were homozygous wildtype or heterozygous (0/1).
A variant was considered as known if it was listed in
dbSNP 151. The range of intronic variants detected per
proband was 2526–3439 (left side, Figure 4), with the
majority of variants per proband were known heterozy-
gous. The range of intergenic variants detected was 8320–
10826 (right side, Figure 4), with the majority of the
variants also being known heterozygous.
Discussion
GCT are primarily sporadic cancers in early childhood or
adolescence with a variety of subtypes. Thus, the mechan-
isms involved in GCT are poorly understood. The identi-
fication of families with relatively little admixture and
multiple GCT cases offers an opportunity to identify
novel genes that may drive or modulate tumor onset and
subtype. In this study, we performed WGS on three such
non-consanguinous families from Finland, where the pro-
band in each family had a different GCT subtype. The
NGS analysis revealed different genes with an autosomal
recessive or de novo inheritance pattern in each family.
Family 1, proband with malignant ovarian teratoma,
analysis yielded three potential autosomal recessive
Crowgey et al Dovepress
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Table 3 Autosomal Recessive and De Novo Variants Identified in Family 3 Proband
Inhertiance
Pattern
Chr:Pos Ref/Alt ID Proband Sister Father Uncle Grand
mother
Sister Grand
father
Gene Names
100/98 101/
98
102/98 103/
98
104/98 98/98 99/98
Autosomal
recessive
4:1388626 ACGTGCCGATGCGGA rs201732211 1/1’ 0/0 0/0 0/0 0/0 0/0 0/0 CRIPAK
11:71238676 CTGCTGCCAGTCCAG
CTGCTGTAAGCCCTG
CTGCTGCCAGTCCAG
CTGCTGTAAGCCCTG
rs1393220620 1/1’ 0/1 0/1 0/0 0/1 0/0 0/0 KRTAP5-7
De novo 1:152284478 A/G rs199888588 0/1 0/0 0/0 0/0 0/0 0/0 0/0 FLG
1:240371009 T/C rs200975594 0/1 0/0 0/0 0/0 0/0 0/0 0/0 FMN2
3:195507970 G/A rs201000518 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC4
3:195507971 G/A rs767776470 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC4
3:195507973 A/C rs200368431 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC4
4:9245723 A/T rs1411951281 0/1 0/0 0/0 0/0 0/0 0/0 0/0 USP17L17
5:140222138 -/CCAACTGATCTGATA
TATTGTATAGTTTAATA
GCTTCTCTAGTCATCT
TAAACAGGGTTGG
rs782205437 0/1 0/0 0/0 0/0 0/0 0/0 0/0 PCDHA1
7:97619354 A/C rs1390112627 0/1 0/0 0/0 0/0 0/0 0/0 0/0 OCM2
8:12286291 C/T rs1211097648 0/1 0/0 0/0 0/0 0/0 0/0 0/0 FAM86B2
9:140773613 -/ACGACACGGAGCCC
TATTTCATCGGGATCT
TT
rs370237172 0/1 0/0 0/0 0/0 0/0 0/0 0/0 CACNA1B
11:1212902 C/G rs200292517 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC5AC
11:1213367 G/A rs748424415 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC5AC
11:1266007 T/C rs774768277 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC5B
11:1266815 G/A rs200874900 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC5B
11:1269763 C/A rs200531133 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC5B
11:1605904 -/CCCCCCACAAGAAC
CGCAGCCCCCC
rs1316818204 0/1 0/0 0/0 0/0 0/0 0/0 0/0 KRTAP5-1
11:64032525 C/G 0/1 0/0 0/0 0/0 0/0 0/0 0/0 PLCB3
12:40882472 -/AGAGACAATTGGACT
ATCAGCTGGAGTGAT
rs1159825088 0/1 0/0 0/0 0/0 0/0 0/0 0/0 MUC19
14:19378000 A/G rs761048370 0/1 0/0 0/0 0/0 0/0 0/0 0/0 OR11H12
18:9887384 T/C rs1442865736 0/1 0/0 0/0 0/0 0/0 0/0 0/0 TXNDC2
18:76754481 -/CCCCCCCCCCCCC
CCCG
0/1 0/0 0/0 0/0 0/0 0/0 0/0 SALL3
X:48887808 T/C rs1286561719 0/1 0/0 0/0 0/0 0/0 0/0 0/0 TFE3
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variants of interest in the following genes: CD109,
IKBKB, and CTNNA3. Although variants had a MAF
<0.01 in the gnomAD genome database, they did have
higher MAF in the Finnish-specific genome data. We
hypothesize that germline variants might cause a predis-
position, but these higher allele frequencies in the Finnish
population indicate that a second hit/additional variant in
combination would be necessary. CD109 is highly asso-
ciated with cancers29 and aberrant expression patterns are
associated with squamous cell carcinoma.30 IKBKB is a
potent activator of the NF-kB pathway, which plays a
major regulatory role during developmental transitions
and the ability of KRAS to transform tissues with aberrant
NF-κB signaling is well established.31 Additionally, dys-
regulation of microRNAs that target IKBKB has been
associated with ovarian tumors.32 The de novo variant
analysis identified rare variants within the gnomAD
Finnish data, with the most interesting gene candidates
being SUPT6H, a histone chaperone, MUC5AC has been
associated with ovarian tumors,23 and FRG1.
An autosomal recessive analysis for family 2 yielded
two potential variants of interest in the following genes:
LONRF2, and ANO7. ANO7 encodes for the protein anoc-
tamin-7, which has calcium-dependent phospholipid
scramblase activity. The variant detected is a loss of func-
tion variant resulting in a stop gain at amino acid 30 in the
translated protein and has previously been published as a
germline variant that associates with significantly shorter
survival rates in prostate cancer subjects.24 The de novo
analysis identified rare variants within the gnomAD
Finnish data and included HS6ST1, PRB2, and DNM2,
which all have been previously linked to cancers.25,26
Family 3 had variants of interest identified in CRIPAK
and KRTAP5-7. CRIPAK is a novel interacting partner of
PAK1.33 PAK1, also referred to as p21-activated kinase 1,
is a complex gene involved in many cellular signaling
pathways including mitosis. Recent studies have described
PAK1 has a relevant oncogene in ovarian carcinoma34 and
breast carcinoma,35 phenotypes recorded within this
family history. However, the pedigree and variant results
HGVS c. (Clinically Relevant) HGVS p. (Clinically Relevant) Effect GnomAD GnomAD
European
Finnish
Missense 0.001105 0.002893
NM_001012503.1:c.329_330insCTGCTGCCAGT
CCAGCTGCTGTAAGCCCTGCTGCTGCCAGT
CCAGCTGCTGTAAGCCCTG
NP_001012521.1:p.
Cys132_Ser133insGlnSerSerCys
CysLysProCysCysCysGlnSerSer
CysCysLysProCysCysCys
Missense 0.0006583 0
NM_002016.1:c.2884T>C NP_002007.1:p.Trp962Arg missense_variant 0.02648 0.000609
NM_001305424.1:c.2909T>C NP_001292353.1:p.Leu970Pro missense_variant 0.002757 0.0000499
NM_018406.6:c.10481C>T NP_060876.5:p.Pro3494Leu missense_variant 0.0004797 0.000198
NM_018406.6:c.10480C>T NP_060876.5:p.Pro3494Ser missense_variant 0.0004074 0
NM_018406.6:c.10478T>G NP_060876.5:p.Ile3493Ser missense_variant 0.001908 0.0001092
NM_001256857.1:c.119A>T NP_001243786.1:p.Lys40Met missense_variant 0.001287 0.0008681
NM_018900.3:c.2394+53868_2394+53869ins
CCAACTGATCTGATATATTGTATAGTTTAA
TAGCTTCTCTAGTCATCTTAAACAGGGTTGG
NP_061734.1:p.Ser411Thrfs frameshift_variant 0.00042 0.0002905
NM_006188.3:c.61+2T>G splice_donor_variant 0.00007551 0
NM_001137610.1:c.593G>A NP_001131082.1:p.Arg198Gln missense_variant 0.002466 0.0007554
NM_000718.3:c.390+1_390+2insACGACACGGA
GCCCTATTTCATCGGGATCTTT
splice_donor_variant 0.005113 0.003842
NM_001304359.1:c.2018C>G NP_001291288.1:p.Thr673Ser missense_variant 0.002578 0.00328
NM_001304359.1:c.2483G>A NP_001291288.1:p.Arg828His missense_variant 0.0006029 0.00007648
NM_002458.2:c.7897T>C NP_002449.2:p.Trp2633Arg missense_variant 0.00009861 0.00004068
NM_002458.2:c.8705G>A NP_002449.2:p.Arg2902His missense_variant 0.0006634 0.0002522
NM_002458.2:c.11653C>A NP_002449.2:p.Arg3885Ser missense_variant 0.002626 0.008074
NM_001005922.1:c.576_577insGGGGGGCTGCG
GTTCTTGTGGGGGG
NP_001005922.1:p.Ser193Glyfs frameshift_variant 0.00003881 0
NM_000932.2:c.2755C>G NP_000923.1:p.Arg919Gly missense_variant
NM_173600.2:c.15716_15717insAGAGACAATTGG
ACTATCAGCTGGAGTGAT
NP_775871.2:p.? disruptive_inframe_
insertion
0 0
NM_001013354.1:c.407A>G NP_001013372.1:p.Asp136Gly missense_variant 0.00398 0.0002808
NM_001098529.1:c.908T>C NP_001091999.1:p.Leu303Pro missense_variant 0.001197 0.0001793
NM_171999.3:c.2489_2490insCCCCCCCCCCCC
CCCCG
NP_741996.2:p.Ser832Profs frameshift_variant
NM_006521.5:c.1589A>G NP_006512.2:p.Glu530Gly missense_variant
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for Family 3’s proband suggest a potential sporadic case of
a neoplasm. A de novo analysis did identify rare variants
in TXNDC2, which is solely expressed in testis and is
predicted to regulate disulfide bonds, and TFE3, a tran-
scription factor linked to pediatric cancers that is ubiqui-
tously expressed in fetal and adult tissues.
A current limitation of this study is the lack of func-
tional studies, which are required to further validate the
biological significance of the variants identified. It is
challenging to functionally validate these types of com-
plex variants associated with a complex phenotype, as
models are difficult to establish. Unfortunately, tumor
testing, which looks for abnormalities in cancer cells,
was not conducted at the time of diagnosis for the pro-
bands. These data could have provided additional insight
for interpreting the germline variants identified.
Furthermore, the non-coding variant analysis identified
numerous variants that are difficult to interpret without
additional functional testing.
Abbreviations
GCT, germ cell tumors; NGS, next-generation sequencing;
WGS, whole-genome sequencing; GATK, genome analy-
sis toolkit; VCF, variant call file; MAF, minor allele fre-
quency; SISu, Sequencing Initiative Suomi.
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